Advisory committees under review
This article was originally published in The Tan Sheet
The Center for Drug Evaluation & Research will review its advisory committee meeting system over the next year to establish best practices surrounding the process, FDA announces May 5. The internal assessment, led by senior management from CDER's Advisors & Consultants Staff, is part of FDA's broader initiative to modernize management of the new drug review process. The evaluation will look at the process for nominating members and choosing consultants, developing competing products lists, screening for conflicts of interest and the role of special government employees outside of advisory committee meetings. The advisory committee system has been a topic of recent public scrutiny. In January, Steve Nissen (Cleveland Clinic Foundation) criticized committees for lacking the means and courage to properly advise FDA on issues of drug safety...
You may also be interested in...
Switzerland’s GeNeuro will study whether its monoclonal antibody temelimab can prevent long-COVID, after data for the first time linked activation of human endogenous retroviruses (HERVs) to the condition and its associated neurological symptoms.
Executives On The Move: CFO Promoted At Novavax, Gilead Gets New Executive Vice President Of Research
Alpha Cognition, F2G and Immune Pharmaceuticals pick up new CEOs, and there is a new chief medical officer at Gemini Therapeutics.
Details of how the FDA plans to conduct remote evaluations of manufacturing facilities during the COVID-19 pandemic have been set out in guidance published by the US agency.